HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed that 1.4% of sequence from treatment-naive patients had IN strand transfer inhibitor (INSTI) RAMs. These mutations confer resistance to raltegravir and elvitegravir. We also observed that 10.1% of the sequences have INSTI accessory RAMs. HIV-1 CRF02_AG was the predominant subtype (44.7%) in this study analyses. The occurrence of INSTI RAMs among the sequences at baseline needs to be monitored carefully.
ZhengR, JenkinsTM, CraigieR: Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci U S A, 1996; 93:13659–13664.
3.
GerettiAM, ArmeniaD, Ceccherini-SilbersteinF: Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis, 2012; 25:677–686.
CastagnoA, MaggioloF, PencoG, et al.: VIKING-3 Study Group Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis, 2014; 210:354–362.
6.
LoizidouEZ, KousiappaI, Zeinalipour-YazdiCD, Van de VijverDA, KostrikisLG: Implications of the HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: Genetic and structural in silico analyses. Biochemistry, 2009; 13:48:4–6.
7.
QuashiePK, OlivieraM, VeresT, et al.: Substitutions in different subtypes of HIV integrase. J Virol, 2015; 89:3163–3175.
8.
MikasiSG, GichanaJO, Van der WaltC, et al.: HIV-1 integrase diversity and resistance-associated mutations and polymorphisms among integrase strand transfer inhibitor-naive HIV-1 patients from Cameroon. AIDS Res Hum Retroviruses, 2020; 36:450–455.
9.
Pineda-PeñaAC, FariaNR, ImbrechtsS, et al.: Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol, 2013; 19:337–348.
10.
TongoM, MartinDP, ZembeL, EitelMN, CarolynW, WendyAB: Characterization of HIV-1 gag and nef in Cameroon: Further evidence of extreme diversity at the origin of the HIV-1 group M epidemic. Virol J, 2013; 10:29.
11.
CahnP, PozniakAL, MingroneH, et al.: Dolutegravir versus raltegravir in antiretroviralexperienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet, 2013; 382:700–708.
12.
AnstettK, CutillasV, FuscoR, MespledeT, WainbergMA: Polymorphic substitution E157Q in HIV-1 integrase increases R263Kmediated dolutegravir resistance and decreases DNA binding activity. J Antimicrob Chemother, 2016; 71:2083–2088.
13.
TurrizianiO, MontagnaC, FalascaF, et al.: Short communication: Analysis of the integrase gene from HIV type 1- positive patients living in a rural area of West Cameroon. AIDS Res Hum Retroviruses, 2012; 28:1729–1733.
